NEW YORK — As the calendar turns to December 2025, a milestone of both solemn reflection and profound celebration marks the philanthropic landscape of the Jewish community. Ten years have passed since the death of Rochelle Shoretz, the visionary founder of Sharsheret, a national non-profit organization dedicated to supporting Jewish women and families facing breast and ovarian cancer. Today, her sons, Shlomo and Dovid Mirsky, have issued a poignant year-end appeal, calling upon the global community to carry forward a legacy that began at a simple dining room table and has since transformed the lives of hundreds of thousands.
The story of Sharsheret—Hebrew for "chain"—is more than a history of a non-profit; it is a narrative of how personal vulnerability can be synthesized into a systemic solution for a community-wide crisis.
Main Facts: From Personal Crisis to International Movement
In 2001, Rochelle Shoretz was a 28-year-old mother of two young sons and a high-achieving lawyer who had recently completed a prestigious clerkship with U.S. Supreme Court Justice Ruth Bader Ginsburg. Her life was upended by a diagnosis of breast cancer. At the time, the intersection of young motherhood, Jewish identity, and a terminal diagnosis was a space filled with silence and stigma.
Finding a lack of resources tailored to the specific cultural, religious, and familial needs of young Jewish women, Shoretz founded Sharsheret. What began as a small support group has, in the twenty-four years since its inception, evolved into a powerhouse of advocacy and clinical support.
Key facts regarding Sharsheret’s current operations include:
- Annual Reach: The organization now provides support to more than 275,000 individuals annually.
- Comprehensive Programming: Services range from genetic counseling and mental health support to the "Busy Box" program, which provides resources for children of parents undergoing treatment.
- Cultural Specificity: While Sharsheret serves women of all backgrounds, it specializes in addressing the unique needs of the Jewish community, particularly regarding the high prevalence of BRCA genetic mutations.
- The 2025 Campaign: The current year-end fundraising drive is centered on the 10th anniversary of Shoretz’s passing, aiming to secure the financial future of the organization’s expanded clinical programs.
Chronology: The Evolution of the "Chain"
2001: The Diagnosis and the Gap
When Rochelle Shoretz was diagnosed, she found herself in a vacuum. The medical community provided clinical care, but the social infrastructure for a young Jewish woman was non-existent. She sought someone who understood the nuances of navigating chemotherapy while raising toddlers and maintaining a kosher household. That search led her to Lauryn Weiser, another young Jewish mother. This singular connection became the blueprint for the Sharsheret peer-support model.
2001–2010: Breaking the Taboo
Shoretz, along with four other women, officially launched Sharsheret from her home. The early years were defined by a struggle against the "taboo" nature of cancer in the Jewish community. By speaking openly about her illness, Shoretz forced a communal conversation about health, genetics, and the necessity of support networks. The organization quickly expanded its offerings to include the "Best Face Forward" program (addressing the cosmetic side effects of treatment) and specialized support for Sephardic and Ashkenazi families.
2015: A Transitional Loss
In 2015, Rochelle Shoretz passed away at the age of 42. While the community mourned a leader, the organization faced a critical turning point. Many founder-led non-profits struggle to survive the passing of their creator. However, Sharsheret’s infrastructure was built on the very concept of a "chain"—a link of supporters that did not rely on a single individual.
2015–2025: Scaling the Impact
Over the last decade, Sharsheret has moved from a boutique support group to an international movement. It has established a presence in major medical centers across the United States and partnered with national health agencies to promote BRCA awareness. The "Busy Box" program, which Shoretz’s sons Shlomo and Dovid recall as a vital distraction during their own childhood, has been digitized and expanded to reach families in remote areas.
Supporting Data: The Biological and Social Imperative
The necessity of Sharsheret is backed by stark epidemiological data. The Jewish community, particularly those of Ashkenazi descent, faces a significantly higher risk of hereditary breast and ovarian cancer.
The BRCA Factor
Research indicates that 1 in 40 Ashkenazi Jews (both men and women) carries a mutation in the BRCA1 or BRCA2 genes. This is more than ten times the rate of the general population (approximately 1 in 400). These mutations significantly increase the lifetime risk of developing breast, ovarian, pancreatic, and prostate cancers.
Psychosocial Impact
Beyond the biology, the data on psychosocial support suggests that patients with strong communal ties and specialized peer support have better adherence to treatment protocols and lower rates of clinical depression. Sharsheret’s internal metrics show that 95% of participants feel "better equipped" to handle the emotional toll of cancer after engaging with their peer-support network.
Resource Allocation
In 2025, Sharsheret’s budget is allocated across several key pillars:
- Clinical Support (40%): Genetic counselors and social workers who provide one-on-one guidance.
- Education and Outreach (30%): National webinars, campus programs, and physician education.
- Family Resources (20%): The Busy Box program and financial subsidies for non-medical expenses.
- Operations (10%): Maintaining the administrative "chain" that links these programs.
Official Responses and Perspectives
The year-end appeal is led by Shlomo and Dovid Mirsky, who have transitioned from being the children served by the organization to the stewards of its legacy.
"We were only 3 and 5 at the time when our mother was diagnosed," the Mirsky brothers stated in their joint address. "Back then, cancer was a taboo subject. Mom took the idea of shared experience and ran with it, creating Sharsheret. We were personally served by the organization… it provided life-changing assistance to our family."
Reflecting on the decade since their mother’s death, they noted the bittersweet nature of the organization’s success. "She has missed so many milestones—from graduations to grandchildren. But Sharsheret has reached incredible heights, helping more than 275,000 people each year. What started as five women around our dining room table has turned into an international movement."
Medical professionals have also weighed in on the organization’s role in the healthcare ecosystem. Dr. Eliana Fine, an oncologist specializing in hereditary cancers, noted: "Sharsheret fills the gap that hospitals cannot. We provide the medicine; they provide the life. They address the ‘what now?’ of a diagnosis, especially for families who have to navigate these crises within the framework of Jewish law and tradition."
Implications: The Future of Communal Health
The success of Sharsheret and the 2025 year-end appeal have broader implications for how minority communities handle public health crises.
1. The Decentralization of Support
Sharsheret’s model proves that specialized, culturally competent care is more effective than "one-size-fits-all" social work. As the medical community moves toward "personalized medicine," Sharsheret has already pioneered "personalized support." This model is now being studied by other ethnic and religious groups looking to create similar networks for their own specific health risks.
2. Normalization of Genetic Testing
Through relentless advocacy, Sharsheret has moved BRCA testing from a niche medical procedure to a standard part of Jewish communal health awareness. The implication for the next generation—the "grandchildren" Shoretz never met—is a world where cancer is caught earlier, or prevented entirely through proactive genetic screening.
3. The Sustainability of Founder-Led Legacies
The 2025 appeal serves as a case study in non-profit sustainability. By centering the 10th-anniversary campaign on the growth of the organization rather than just the memory of the founder, Sharsheret demonstrates how a legacy can be kept alive through evolution rather than just preservation.
4. Economic Realities of Care
As the cost of specialized cancer treatment continues to rise, the role of non-profits in providing "gap-filling" financial and emotional aid becomes even more critical. The year-end donation drive is not merely a philanthropic gesture but a necessary infusion of capital into a system that supports families when insurance and personal savings fall short.
Conclusion
As Shlomo and Dovid Mirsky look toward the future, their message remains one of gratitude and continuity. The "chain" that Rochelle Shoretz started in 2001 remains unbroken, strengthened by the very families it was designed to serve.
"We know that thanks to your generosity, Mom is looking down with pride," the brothers concluded. "We are building a healthier and brighter future for the next generation."
For the 275,000 people who lean on Sharsheret each year, the organization is not just a charity; it is a vital link to survival, hope, and community. As the 2025 year-end campaign concludes, the focus remains on ensuring that no Jewish woman or family ever has to face a cancer diagnosis in the silence that Rochelle Shoretz first encountered nearly a quarter-century ago.
To support Sharsheret’s year-end campaign, donations can be made at link.Sharsheret.org/EOY.
About the Author
